Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 2,319 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multiple Myeloma Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

NCT00464178
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Nov 4, 2026, 10:52 PM EST
Not listed Not applicable Interventional

Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection

NCT01042717
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkins Lymphoma
Interventions
Plerixafor
Drug
Lead sponsor
Shi, Patricia, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Nov 4, 2026, 10:52 PM EST
Completed Phase 2 Interventional Results available

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma

NCT00185614
View directory record Official record
Conditions
Blood Cancer, Multiple Myeloma
Interventions
Autologous hematopoietic cell transplant (Auto-HCT), Allogeneic hematopoietic cell transplant (Allo-HCT), Cyclophosphamide, Filgrastim, Melphalan, Total body irradiation (TBI), Cyclosporine (CSP), Mycophenolate Mofetil (MMF)
Procedure · Drug · Radiation
Lead sponsor
Wen-Kai Weng
Other
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Nov 4, 2026, 10:52 PM EST
Completed No phase listed Observational

Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation

NCT02598752
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Hematological Malignancy, Leukemia, Lymphoma, Myeloma
Interventions
Symptom-limited cardiopulmonary exercise test (CPET), Resting assessment of cardiac function by echocardiography, Post-exercise assessment of cardiac function by echocardiography, Pulmonary function, Patient-reported outcomes questionnaire
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Nov 4, 2026, 10:52 PM EST
Recruiting Phase 1 Interventional

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

NCT03909412
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Cyclophosphamide, Dexamethasone, Granulocyte Colony-Stimulating Factor
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Active, not recruiting Phase 3 Interventional

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

NCT02659293
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Carfilzomib, Dexamethasone, Lenalidomide (Control)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Terminated Phase 1 Interventional Results available

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

NCT01251952
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Denileukin Diftitox (Ontak)
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Nov 4, 2026, 10:52 PM EST
Completed Phase 1 Interventional

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01689987
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Cyclophosphamide, Dexamethasone, Hydroxychloroquine, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Nov 4, 2026, 10:52 PM EST
Recruiting No phase listed Observational

Sleep Apnea in Patients With MGUS and MM

NCT04114084
View directory record Official record
Conditions
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
Bone Marrow Aspirate and Biopsy
Procedure
Lead sponsor
Michael Tomasson
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 4, 2026, 10:52 PM EST
Completed Phase 1 Interventional

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

NCT02352558
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
BBI608, Dexamethasone, Bortezomib, Imatinib, Ibrutinib
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Denver, Colorado • Indianapolis, Indiana • Germantown, Tennessee + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Nov 4, 2026, 10:52 PM EST
Terminated Phase 1 Interventional

Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

NCT04142619
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
UCARTCS1A
Biological
Lead sponsor
Cellectis S.A.
Industry
Eligibility
18 Years to 64 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Nov 4, 2026, 10:52 PM EST
Terminated Phase 1Phase 2 Interventional

Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers

NCT00861965
View directory record Official record
Conditions
Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma
Interventions
AlloStim-8
Biological
Lead sponsor
Mirror Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Nov 4, 2026, 10:52 PM EST
Completed Phase 2 Interventional Results available

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

NCT03224507
View directory record Official record
Conditions
Multiple Myeloma
Interventions
KRdD followed by auto-HCT, KRdD only
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • Portland, Oregon • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Nov 4, 2026, 10:52 PM EST
Not listed Phase 1Phase 2 Interventional

T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant

NCT00048464
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Infusion of Activated & Expanded Autologous T Cells
Procedure
Lead sponsor
Xcyte Therapies
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2006 · Synced Nov 4, 2026, 10:52 PM EST
Terminated Phase 1 Interventional

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

NCT04892264
View directory record Official record
Conditions
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Biospecimen Collection, Skeletal Survey X-Ray, Low Dose Computed Tomography of the Whole Body, Bone Marrow Aspiration, Bone Marrow Biopsy
Biological · Drug · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Nov 4, 2026, 10:52 PM EST
Active, not recruiting Early Phase 1 Interventional

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

NCT05560399
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide, Elotuzumab, Dexamethasone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Completed Phase 2 Interventional

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

NCT00005804
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Nov 4, 2026, 10:52 PM EST
Terminated Phase 1 Interventional

Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

NCT04521335
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Disulfiram, Copper Gluconate
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Nov 4, 2026, 10:52 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

NCT06644625
View directory record Official record
Conditions
Multiple Myeloma, Multiple Myeloma Progression, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Plasma Cell Disorders
Interventions
Blood draw for the laboratory assessment
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
30 Years and older
Enrollment
1,665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2035
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 4, 2026, 10:52 PM EST
Completed Phase 2 Interventional

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

NCT00313625
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
busulfan, melphalan, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Nov 4, 2026, 10:52 PM EST
Terminated Phase 1 Interventional

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

NCT04702425
View directory record Official record
Conditions
Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
Interventions
VOB560, MIK665
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Nov 4, 2026, 10:52 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

NCT02294487
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Nov 4, 2026, 10:52 PM EST
Withdrawn Early Phase 1 Interventional

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

NCT03591614
View directory record Official record
Conditions
Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
Interventions
DKK1
Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Nov 4, 2026, 10:52 PM EST
Terminated Phase 1Phase 2 Interventional

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT03492138
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ONC201, Ixazomib, Dexamethasone
Drug
Lead sponsor
Ajai Chari
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Nov 4, 2026, 10:52 PM EST